Celcuity

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Celcuity and other ETFs, options, and stocks.

About CELC

Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. 

CEO
Brian F. Sullivan
CEOBrian F. Sullivan
Employees
155
Employees155
Headquarters
Minneapolis, Minnesota
HeadquartersMinneapolis, Minnesota
Founded
2012
Founded2012
Employees
155
Employees155

CELC Key Statistics

Market cap
4.31B
Market cap4.31B
Price-Earnings ratio
-22.68
Price-Earnings ratio-22.68
Dividend yield
Dividend yield
Average volume
2.27M
Average volume2.27M
High today
High today
Low today
Low today
Open price
$86.13
Open price$86.13
Volume
0.00
Volume0.00
52 Week high
$151.02
52 Week high$151.02
52 Week low
$13.47
52 Week low$13.47

Stock Snapshot

With a market cap of 4.31B, Celcuity(CELC) trades at $88.38. The stock has a price-to-earnings ratio of -22.68.

During the trading day, Celcuity(CELC) stock saw an opening price of $86.13, a peak of —, and a bottom of —.

Trading activity shows a volume of 0, compared to an average daily volume of 2.27M.

The stock's 52-week range extends from a low of $13.47 to a high of $151.02.

The stock's 52-week range extends from a low of $13.47 to a high of $151.02.

CELC News

Simply Wall St 2d
Celcuity Stock May Be Overvalued After REVTORPYK Approval

Celcuity stock has delivered a very large 3 year return, yet its recent pullback and a mixed set of valuation checks raise questions about how much of the good...

Celcuity Stock May Be Overvalued After REVTORPYK Approval
TipRanks 5d
Celcuity falls -19.7%

Celcuity (CELC) is down -19.7%, or -$21.87 to $89.18. TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique...

TipRanks 5d
Celcuity: Buy Rating Reaffirmed on Gedatolisib’s Multi-Billion-Dollar Potential, $165 Price Target Unchanged

Celcuity, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Bradley Canino from Guggenheim maintained a Buy rating on the...

Analyst ratings

100%

of 12 ratings
Buy
100%
Hold
0%
Sell
0%

More CELC News

TipRanks 6d
Celcuity announces FDA approval of Revtorpyk

Celcuity (CELC) announced that the U.S. Food and Drug Administration approved REVTORPYK for the treatment of patients with hormone receptor positive, human epid...

People also own

Based on the portfolios of people who own CELC. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.